Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV Presented at the 44th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, October 6-10, 2002

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 735-742

  Michalski, Jeff M ^a   Winter, K ^b   Purdy, James A ^a   Perez, Carlos A ^a   Ryu, Janice K ^c   Parliament, Matthew B ^d   Valicenti, Richard K ^e   Roach III, Mack ^f   Sandler, Howard M ^g   Markoe, Arnold M ^h   Cox, James D ⁱ  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Conformal therapy; Dose escalation; Prostate cancer; Toxicity

Indexed keywords

ANTIGENS; DOSIMETRY; HEALTH RISKS; PATIENT TREATMENT; RADIOTHERAPY; TOXICITY;

ELECTIVE PELVIC RADIOTHERAPY; PROSTATE CANCER;

ONCOLOGY;

AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SEMINAL VESICLE; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 10744221165     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)01578-5     Document Type: Article

References (19)

1. Michalski J., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys. 46:2000;391-402.
2. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 54:2002;1036-1046.
3. Lawton C.A., Won M., Pilepich M.V., et al. Long-term treatment sequelae following external beam irradiation adenocarcinoma of the prostate Analysis of RTOG studies 7506 and 7706 . Int J Radiat Oncol Biol Phys. 21:1991;935-939.
4. AJCC cancer staging manual. 4th ed:1992;Lippincott-Raven, Philadelphia.
5. ICRU Report 50: Prescribing, recording, and reporting photon beam therapy. 1993;International Commission on Radiation Units and Measurement, Bethesda.
6. Diaz A., Roach M., Marquez C., et al. Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 30:1994;323-329.
7. Pilepich M.V., Asbell S.O., Krall J.M., et al. Correlation of radiotherapeutic parameters and treatment related morbidity Analysis of RTOG study 77-06 . Int J Radiat Oncol Biol Phys. 13:1987;1007-1012.
8. Pilepich M.V., Krall J.M., Sause W.T., et al. Correlation of radiotherapeutic parameters and treatment related morbidity in carcinoma of the prostate - Analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys. 13:1987;351-357.
9. Kalbfleisch J.D., Prentice R.L. The statistical analysis of failure time data. 1980;John Wiley & Sons, New York. p. 167-169.
10. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 16:1988;1141-1154.
11. Cox D.R. Regression models and life tables. J Royal Stat Soc B. 34:1972;187-229.
12. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer Preliminary results of a randomized trial . Int J Radiat Oncol Biol Phys. 48:2000;635-642.
13. Zelefsky M.J., Cowen D., Fuks Z., et al. Long-term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer. 85:1999;2460-2468.
14. Lee W.R., Hanks G.E., Hanlon A.L., et al. Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer Further evidence for a significant dose effect . Int J Radiat Oncol Biol Phys. 35:1996;251-257.
15. Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101.
16. D'Souza W.D., Thames H.D. Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys. 51:2001;1-3.
17. Duchesne G.M., Peters L.J. What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 44:1999;747-748.
18. King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys. 51:2001;213-214.
19. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys. 51:2001;213-214.